Stores clear pediatric cough and cold remedies from shelves

21 October 2007

US retail outlets have removed cough and cold remedies for children from their shelves, following the recent announcement by manufacturers. The decision pre-empts a meeting of the Food and Drug Administration to consider expert recommendations on the future availability of over-the-counter products for children under two-years old.

Both the Stop & Shop Supermarket Company and Giant Food issued statements listing 11 formulations of affected products. These were: Concentrated Tylenol Infants' Drops Plus Cold & Cough; Concentrated Tylenol Infants' Drops Plus Cold & Cough Club Tray; PediaCare Infant Dropper Long-Acting Cough; PediaCare Infant Dropper Decongestant (containing pseudoephedrine); PediaCare Infant Dropper Decongestant & Cough; PediaCare Infant Dropper Decongestant & Cough (containing pseudoephedrine); CareOne Infant Cough and Cold Cherry 0.5oz; Triaminic Infant & Toddler Thin Strips Decongestant; Triaminic Infant & Toddler Thin Strips Decongestant Plus Cough; Little Colds Decongestant + Cough 1oz; and Little Colds Multi Symptom Cold 1oz.

Tylenol is marketed by US health care giant Johnson & Johnson while Triaminic is a brand of Switzerland-based drug major Novartis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight